This round is no longer accepting investments, but hundreds just like it are live now.

Log In

INVEST IN LIFE RECOVERY SYSTEMS TODAY!

Rapid Emergency Body Cooling System

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$86,589.36 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS
711 Kimball Ave
Alexandria, LA 71301

TEAM

Robert Freedman, M.D.
Robert Freedman, M.D.
Co-Founder, Chairman of the Board & Chief Medical Officer

Is the co-founder, co-inventor, Chairman of the Board of Directors and Chief Medical and Strategy Officer. He is an interventional cardiologist, was a Flight Surgeon trained at the U.S. Air Force School of Aerospace Medicine and trained in Cardiology at The University of Texas Health Science Center in Houston. Over the last three years (2015-2018) Dr. Freedman has served as Chairman of the Board of Managers and Chief Medical Officer of Life Recovery Systems, LLC, working out of its business office in Alexandria, LA. During that time he has also served as Manager of Freedman Memorial Cardiology in Alexandria, LA.

Robert Schock, Ph.D.
Robert Schock, Ph.D.
Co-Founder, Vice President of R&D

The co-founder, co-inventor and Vice President of Research & Development. He received a Ph.D. in Biomedical Engineering from Rensselaer Polytechnic Institute and has over 20 years of experience leading R&D groups in cardiac assist, critical care and anesthesia. Previously he managed an R&D Group in Critical Care and Anesthesia for Mallinckrodt Pharmaceutical. Over the last three years (2015-2018) Dr. Schock has served as Vice President of Research and Development of Life Recovery Systems, LLC, working out of its Research and Manufacturing facility in Kinnelon, NJ.

Richard Hettenbach

Richard Hettenbach

Vice President of Operations

Is the Vice President of Operations. He has over 30 years of experience in Pharmaceutical R&D, Medical Device Quality Assurance, Regulatory and Clinical Affairs. He has held positions at Sandoz Pharmaceuticals, C.R. Bard and Ackrad Laboratories. Over the last three years Mr. Hettenbach has served as Vice President of Operations of Life Recovery Systems, LLC in its Kinnelon, NJ office. Over that same period he has also worked as a Regulatory Affairs consultant in his private consulting company, Medqra, LLC, which is based in Morris Plains, NJ.

Coan Knight

Coan Knight

Financial Management

is the Financial Manager. He is a CPA and a retired Principal in Knight Masden, a professional accounting corporation based in Alexandria, LA. He was one of the original founders of the accounting firm and served in management for 34 years before retirement in 2004 He has assisted Life Recovery Systems from 2005 to 2018 as a financial consultant.

Stephen Katz, MD

Stephen Katz, MD

Member of Board of Managers

President, Central Louisiana Anesthesia & Pain Management Ctr. October 1, 1995 to present. Secretary, Central Louisiana Surgical Hospital January 1, 2016 - December 31, 2018 Served on the Life Recovery Systems Board of Managers from February 1, 2015 to the present.

Glenda Stock

Glenda Stock

Member of Board of Managers

President, GRITS Entities, LLC Back Office Support September, 2017 - Present Producer, On Point Talk Television Television Talk Show May, 2014 - Present Served on the Life Recovery Systems Board of Managers From February 1, 2015 to the present.

Nell Shehee

Nell Shehee

Member of Board Managers

Co-owner and Vice-President of Kilpatrick Life Insurance Companies and Rose-Neath Funeral Homes, Crematorium and Cemeteries and Flower Shop 1976-Present Served on the Life Recovery Systems Board of Managers from February 1, 2015 to the present

David Baker, MD

David Baker, MD

Member of Board of Managers

Retired after 37 years from private invasive cardiology practice in Lafayette, Louisiana. Former Board Member of two general hospitals and one cardiovascular specialty hospital. Served on the Life Recovery Systems Board of Managers from February 1, 2015 to the present.

TERMS

Life Recovery Systems
Overview
PRICE PER SHARE
$9.57
DEADLINE
Nov 3, 2018
VALUATION
$21.39M
FUNDING GOAL
$10k - $107k
Breakdown
MIN INVESTMENT
$248.82
MAX INVESTMENT
$106,992.60
MIN NUMBER OF SHARES OFFERED
1,044
MAX NUMBER OF SHARES OFFERED
11,180
OFFERING TYPE
Equity
SHARES OFFERED
Class B Common Units

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$198,953

$230,860

Cash & Cash Equivalents

$1,783

$7,617

Accounts Receivable

$0

$23,200

Short-Term Debt

$159,391

$213,148

Long-Term Debt

$3,024,616

$2,771,255

Revenue & Sales

$104,330

$237,896

Costs of Goods Sold

$76,515

$124,007

Taxes Paid

$0

$0

Net Income

-$230,344

-$133,512

Irregular Use of Proceeds

Funds from this offering and other sources may be used to provide for expenses incurred for sale of the company. At this time there are no prospective buyers of the company and no anticipated costs in connection with seeking a buyer.

PRESS

Article Image
Quick cooling ThermoSuit may prevent brain damage in stroke patients

Tulane researchers are testing rapid induction of therapeutic hypothermia as an investigational treatment for stroke (Note: FDA has cleared the ThermoSuit System as a thermal regulating system indicated for patient temperature reduction where clinically indicated, e.g. in hyperthermic patients).

Article Image
Back from the Brink

This award-winning documentary interviews a patient who was treated with the ThermoSuit in a Canadian study (Note: FDA has cleared the ThermoSuit System as a thermal regulating system indicated for patient temperature reduction where clinically indicated, e.g. in hyperthermic patients).

ALL UPDATES

10.18.18

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Life Recovery Systems has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Life Recovery Systems be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

08.30.18

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Life Recovery Systems offering. Here's an excerpt describing the specifics of the change:


Life Recovery Systems HD LLC is extending their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

08.15.18

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Life Recovery Systems has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Life Recovery Systems be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

06.21.18

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Life Recovery Systems has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Life Recovery Systems be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

06.19.18

The Sues' Story

04.12.18

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Life Recovery Systems has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Life Recovery Systems be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

03.26.18

Amending our Securities Offering

Hello! Recently, a change was made to the Life Recovery Systems offering. Here's an excerpt describing the specifics of that change:


Life Recovery Systems HD, LLC has extended their campaign and added their 2017 financials.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Life Recovery Systems.

JOIN THE DISCUSSION

0/2500

JM
Jeremy Martinez

5 INVESTMENTS

4 months ago

I found this on the website: FOR IMMEDIATE RELEASE Tuesday, March 1, 2022 FDA APPROVES FURTHER EXPANSION OF CLINICAL STUDY INVESTIGATING COOLING OF STROKE PATIENTS Life Recovery Systems has been granted approval by the US Food and Drug Administration (FDA) to further expand its clinical study of the use of the ThermoSuit® System in the treatment of ischemic stroke (the study, which is being conducted under an investigational device exemption (IDE)). Under the revised IDE up to six hospitals are now allowed to participate in the study. Sites which have joined the study include Tulane Medical Center, PRISMA Health/USC, Geisinger Medical Center, and Geisinger Wyoming Valley Medical Center. The company is seeking two additional sites to help with the investigation. According to Dr. Robert Schock, Vice President of R&D for the firm, “We continue to be pleased with the results we have seen thus far as our rapid cooling treatment has been investigated in victims of stroke. Preliminary data predict that cooling will be most effective if provided close to the time of reperfusion. Enrollments have been slow during the COVID pandemic, but with COVID rates decreasing and study sites increasing we expect the pace of the study to pick up significantly.” Patients in the trial are being cooled while under sedation, with the intent of reaching a state of therapeutic hypothermia in approximately 30 to 40 minutes. The ThermoSuit System uses direct liquid contact with the patient to reduce core body temperature. A thin film of ice water is circulated over the patient’s body until the temperature reaches a pre-set limit, at which point the water is automatically removed from the suit. The system is easily set up by nurses or technicians in minutes and cools to a therapeutic temperature of 33 degrees in about 30 to 40 minutes. The patient is then removed from the suit and remains cold for hours, without the need for further maintenance, allowing unencumbered access for subsequent imaging or treatment. A similar trial investigating the cooling of victims of acute myocardial infarction has also received IDE approval, and will be pursued at a later date, using input obtained from the SISCO stroke trial.

0

0

JM
Jeremy Martinez

5 INVESTMENTS

4 months ago

Any updates?

0

0

GC
Giovanni Canu

10 months ago

Hello, No updates in three years!! This is a shame

0

0

GC
Giovanni Canu

4 years ago

hello guys, can you provide some update on the roadmap? thank you!

0

0

PW
Prescott Woodford

3 INVESTMENTS

5 years ago

My name is Prescott. I would be very happy to assist you with your funding goals. We do NOT require any upfront fees for funding. If you are truly serious, kindly give me a call when you get this. Thank you. Regards, Prescott Woodford CEO/Principal pwoodford@woodford-associates.com ___________________________________________ Woodford & Associates 'Finding Funds For Your Business And Personal Needs' woodford-associates.com

0

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$86,589.36
INVESTORS
85
MIN INVEST
$248.82
VALUATION
$21.39M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.